School of Medicine
Background: Immunotherapy for multiple myeloma (MM) has been the focus in recent years due to its myeloma-specific immune responses. We reviewed the literature on non-Food and Drug Administration (FDA) approved monoclonal antibodies (mAbs) to highlight future perspectives. We searched PubMed, EMBASE, Web of Science, Cochrane Library and ClinicalTrials.gov to include phase I/II clinical trials. Data from 39 studies (1906 patients) were included. Of all the agents, Isatuximab (Isa, anti-CD38) and F50067 (anti-CXCR4) were the only mAbs to produce encouraging results as monotherapy with overall response rates (ORRs) of 66.7% and 32% respectively. Isa showed activity when used in combination with lenalidomide (Len) and dexamethasone (Dex), producing a clinical benefit rate (CBR) of 83%. Additionally, Isa used in combination with pomalidomide (Pom) and Dex resulted in a CBR of 73%. Indatuximab Ravtansine (anti-CD138 antibody-drug conjugate) produced an ORR of 78% and 79% when used in combination with Len-Dex and Pom-Dex, respectively. Conclusions: Combination therapy using mAbs such as indatuximab, pembrolizumab, lorvotuzumab, siltuximab or dacetuzumab with chemotherapy agents produced better outcomes as compared to monotherapies. Further clinical trials investigating mAbs targeting CD38 used in combination therapy are warranted.
Digital Commons Citation
Iftikhar, Ahmad; Hassan, Hamza; Iftikhar, Nimra; Mushtaq, Adeela; Sohail, Atif; Rosko, Nathaniel; Chakraborty, Rajshekhar; Razzaq, Faryal; Sandeep, Sonia; Valent, Jason Neil; Kanate, Abraham Sebastian; and Anwer, Faiz, "Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: A Systematic Review of Agents under Clinical Development" (2019). Faculty & Staff Scholarship. 2049.
Iftikhar, A., Hassan, H., Iftikhar, N., Mushtaq, A., Sohail, A., Rosko, N., Chakraborty, R., Razzaq, F., Sandeep, S., Valent, J. N., Kanate, A. S., & Anwer, F. (2019). Investigational Monoclonal Antibodies in the Treatment of Multiple Myeloma: A Systematic Review of Agents under Clinical Development. Antibodies, 8(2), 34. https://doi.org/10.3390/antib8020034